Ribavirin Tablets

Pharmacology: Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. This product does not change the adsorption, invasion and uncoating of viruses, nor does it induce the production of interferon. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus. Toxicological animal experiments have found that this product can induce benign tumors of the breast, pancreas, pituitary and adrenal glands, but its carcinogenicity to humans has not been confirmed. The drug can cause malformations of the head, palate, eyes, jaw, bones and gastrointestinal tract in animals such as hamsters, and reduce the survival of offspring, but primate experiments have not found any effect of the drug on the fetus. Heart damage occurred in mice, rats and monkeys when they were given ribavirin orally at doses of 30, 36 and 120 mg/kg or for more than 4 weeks (equivalent to the human dose: 4.8, 12.3 and 111.4 mg/kg for a child weighing 5 kg, or 2.5, 5.1 and 40 mg/kg for an adult weighing 60 kg. All the above are calculated based on body surface area).

The main ingredient of this product is ribavirin. Its chemical name is 1-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide. Molecular formula: C8H12N4O5. Molecular weight: 244.21.

This product is white tablets.

It is suitable for viral pneumonia and bronchitis caused by respiratory syncytial virus, and herpes virus infection of the skin.

Oral 1. Viral respiratory tract infection: Adults take 0.15g once, 3 times a day, for 7 days. 2. Skin herpes virus infection: Adults take 0.3g once, 3 times a day, for 7 days. 3. Children take 10mg/kg per day, divided into 4 doses, for 7 days. The oral dosage for children under 6 years old is not determined.

Common adverse reactions include anemia and fatigue, which disappear after stopping the drug. Less common adverse reactions include fatigue, headache, insomnia, loss of appetite, nausea, vomiting, mild diarrhea, constipation, etc., and can cause a decrease in red blood cells, white blood cells and hemoglobin.

It is forbidden for people who are allergic to this product and pregnant women.

Precautions for children: The oral dose for children under 6 years old has not been determined. Precautions for pregnancy and lactation: 1. This product has a strong teratogenic effect. A daily dose of 1 mg/kg in rabbits can cause embryo damage, so it is contraindicated for pregnant women and women who may become pregnant (this product is eliminated very slowly in the body and cannot be completely eliminated from the body 4 weeks after stopping the drug). 2. A small amount of the drug is excreted through breast milk and is toxic to both mother and offspring. Therefore, breastfeeding women should stop breastfeeding during medication and their breast milk should be discarded. Since respiratory syncytial virus infection in lactating women is self-limiting, this product is not used in such cases. Precautions for the elderly: It is not recommended for the elderly.

This product has an antagonistic effect when used together with zidovudine, because this product can inhibit the conversion of zidovudine into active zidovudine phosphate.

Keep away from light and store in sealed container.

20mg

24 months

Sichuan Meidakang Pharmaceutical Co., Ltd.

• Founded in:

  2000-08-22

• Address:

  Jinhe East Road, Shifang City, Sichuan Province

• Tax NO.:

  9151060062089018XJ

• Registered Funds:

  116 million yuan

• Website:

  Log in to view

• Email:

  Log in to view